



## Resource: ART Drug-Drug Interactions

April 2023

**Table 11: Rilpivirine (RPV) Interactions** (also see drug package inserts)

The combination CAB/RPV antiretroviral therapy regimen can be used during an oral medication lead-in period and then as monthly long-acting injections; also see Table 6: Cabotegravir (CAB) Interactions.

Class or Drug	Mechanism of Action	Clinical Comments
Macrolides	Coadministration may increase RPV levels.	Consider alternatives. Increased RPV levels when combined with macrolides may lead to increased risk of torsades de pointes.
Proton pump inhibitors (PPIs) [Schafer and Short 2012]	<ul style="list-style-type: none"> <li>PPIs inhibit gastric acid secretion by proton pumps, thereby increasing gastric pH.</li> <li>Oral RPV requires acidic environment for optimal absorption.</li> </ul>	<ul style="list-style-type: none"> <li>Concurrent use of PPIs with <i>oral</i> RPV is contraindicated.</li> <li>Use of PPIs with <i>injectable</i> RPV is acceptable.</li> </ul>
Histamine-2 receptor antagonists (H2RAs) [Schafer and Short 2012]	<ul style="list-style-type: none"> <li>H2RAs inhibit gastric acid secretion by proton pumps, thereby increasing gastric pH.</li> <li>Oral RPV requires acidic environment for optimal absorption.</li> <li>Concomitant use may decrease RPV absorption.</li> </ul>	<ul style="list-style-type: none"> <li>Administer H2RA at least 12 hours before or 4 hours after.</li> <li>Use lowest effective dose.</li> <li>Administer with food.</li> <li>Use of H2RAs with <i>injectable</i> RPV is acceptable.</li> </ul>
Antacids [Schafer and Short 2012]	<ul style="list-style-type: none"> <li>Antacids increase gastric pH.</li> <li>RPV requires acidic environment for optimal absorption.</li> <li>Concomitant use may decrease RPV absorption.</li> </ul>	Administer antacids 2 hours before or 4 hours after.
GLP-1 agonists	Caution needed when coadministering with RPV and GLP-1 agonists, such as exenatide, due to their potential to inhibit gastric secretion, thereby reducing RPV absorption. Furthermore, exenatide may slow gastric emptying.	May recommend RPV dosing 4 hours before.
Dexamethasone [Welz, et al. 2017]	Dexamethasone is a CYP3A inducer, which is primarily responsible for metabolism of RPV.	<b>Dexamethasone (systemic):</b> <ul style="list-style-type: none"> <li>Concomitant use is contraindicated; consider alternative steroids.</li> <li>If using more than a single oral or IM dose, consider an alternative NNRTI after consultation with experienced HIV care provider (see package inserts for <a href="#">Cabenuva</a> and <a href="#">Edurant</a>).</li> </ul>
Antiarrhythmic drugs [Sanford 2012]	Supratherapeutic RPV doses have caused QT prolongation and additive effects may be seen.	Avoid concomitant use (may cause QT prolongation and torsades de pointes).
Long-acting beta agonists (LABAs)	RPV and drugs from LABA class may both theoretically increase QT interval, especially at high doses.	<ul style="list-style-type: none"> <li>No dose adjustments are necessary.</li> <li>Do not use more LABA than recommended; this can increase risk of QT prolongation.</li> </ul>

**Table 11: Rilpivirine (RPV) Interactions** (also see drug package inserts)

The combination CAB/RPV antiretroviral therapy regimen can be used during an oral medication lead-in period and then as monthly long-acting injections; also see Table 6: Cabotegravir (CAB) Interactions.

Class or Drug	Mechanism of Action	Clinical Comments
Antipsychotics	No significant interactions reported.	No dose adjustments are necessary, but avoid excess doses of either antipsychotic or RPV because excess doses of both drugs may increase risk of QT prolongation.
Carbamazepine, oxcarbazepine, phenobarbital, phenytoin	Coadministration may significantly reduce RPV concentrations through induction of CYP450, UGT1A, and/or P-gP system.	Concomitant use is contraindicated with oral and injectable RPV (see package inserts for <a href="#">Cabenuva</a> and <a href="#">Edurant</a> ).
Methadone, buprenorphine (BUP)	<ul style="list-style-type: none"> <li>• <b>BUP:</b> No significant interactions are expected.</li> <li>• <b>Methadone:</b> RPV mildly reduces methadone concentrations.</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Methadone:</b> Monitor for signs of methadone withdrawal; increase dose as necessary.</li> <li>• <b>Methadone, BUP:</b> Use cautiously with RPV; supratherapeutic RPV doses have been known to cause increase in QT prolongation.</li> </ul>
Rifabutin, rifampin, rifapentine	Coadministration may significantly reduce RPV concentrations through induction of CYP450, UGT1A, and/or P-gP system.	<ul style="list-style-type: none"> <li>• <b>Rifabutin:</b> <ul style="list-style-type: none"> <li>– <a href="#">Oral RPV:</a> Increase RPV dose to 50 mg once daily [DHHS 2021].</li> <li>– Injectable RPV: Concomitant use is contraindicated.</li> </ul> </li> <li>• <b>Rifampin, rifapentine:</b> Concomitant use with <a href="#">oral and injectable RPV</a> is contraindicated [FDA 2021].</li> </ul>
Strong inducers or inhibitors of CYP3A	RPV is a CYP3A substrate, and as such, drugs that affect its metabolism affect its concentrations.	<ul style="list-style-type: none"> <li>• Avoid concomitant use if possible.</li> <li>• Dose adjustments of RPV are not recommended.</li> <li>• Consider alternative concomitant agents.</li> </ul>
Mpox treatments [a]	<b>Tecovirimat</b> is a weak inducer of CYP3A and a weak inhibitor of CYP2C8 and CYP2C19; use may increase or decrease plasma concentrations of other medications.	<ul style="list-style-type: none"> <li>• <b>Tecovirimat</b> may reduce NNRTI levels, though effects are not likely to be clinically relevant. No dose adjustment in either drug is necessary.</li> <li>• <b>Brincidofovir, cidofovir, VIGIV:</b> Drug interactions are unlikely.</li> </ul>

**Abbreviations:** ARV, antiretroviral; AUC, area under the curve; CAB, cabotegravir; CYP, cytochrome P450; GLP-1, glucagon-like peptide-1; IM, intramuscular; NNRTI, non-nucleoside reverse transcriptase inhibitor; P-gP, P-glycoprotein; TDM, therapeutic drug monitoring; VIGIV, vaccinia immune globulin intravenous.

**Note:**

a. No data are currently available on effects related to concurrent use of tecovirimat and HIV medications. However, [midazolam AUC was reduced by 32% with concomitant tecovirimat use](#), and some experts recommend caution due to the mild CYP3A4 induction associated with tecovirimat. Among them is [University of Liverpool HIV Drug Interactions](#), which makes the following dosing change recommendations, although they are not based on any clinical data: Increase dose to 50 mg daily for the duration of tecovirimat treatment and for 2 weeks after tecovirimat is stopped.

**No significant interactions/no dose adjustments necessary:** Common oral antibiotics (Table 19); drugs used as antihypertensive medicines (Table 20); anticoagulants (Table 21); antiplatelet drugs (Table 22); statins (Table 23); asthma and allergy medications (Table 27); antidepressants (Table 30); benzodiazepines (Table 31); sleep medications (Table 32); anticonvulsants not specifically stated above (Table 34); nonopioid pain medications (Table 35); opioid analgesics and tramadol (Table 36); erectile and sexual dysfunction agents (Table 38); alpha-adrenergic antagonists for benign prostatic hyperplasia (Table 39); tobacco and smoking cessation products (Table 40); alcohol, disulfiram, and acamprosate (Table 41); naloxone and naltrexone (Table 42); immunosuppressants (Table 43); COVID-19 therapeutics (Table 45); gender-affirming hormones (Table 47).

## References

- DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV: Drug-drug interactions: Role of therapeutic drug monitoring in managing drug-drug interactions. 2021 Jun 3. <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/overview> [accessed 2018 Jul 6]
- FDA(b). Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. 2021 Jan. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/212888s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf) [accessed 2021 May 28]
- Sanford M. Rilpivirine. *Drugs* 2012;72(4):525-41. [PMID: 22356290] <https://pubmed.ncbi.nlm.nih.gov/22356290>
- Schafer JJ, Short WR. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review. *Antivir Ther* 2012;17(8):1495-1502. [PMID: 22878339] <https://pubmed.ncbi.nlm.nih.gov/22878339>
- Welz T, Wyen C, Hensel M. Drug interactions in the treatment of malignancy in HIV-infected patients. *Oncol Res Treat* 2017;40(3):120-27. [PMID: 28253501] <https://pubmed.ncbi.nlm.nih.gov/28253501>